AVTX-803 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
65原発性免疫不全症候群2

65. 原発性免疫不全症候群


臨床試験数 : 500 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05754450
(ClinicalTrials.gov)
April 21, 20236/2/2023An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type IIA Phase 3, Open-Label, Extension Study to Assess the Long-term Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II (LAD II)Leukocyte Adhesion DeficiencyDrug: AVTX-803Avalo Therapeutics, Inc.NULLNot yet recruiting6 Months75 YearsAll2Phase 3United States
2NCT05462587
(ClinicalTrials.gov)
July 28, 202228/6/2022A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type IIA Phase 3, Randomized, Double-blind, Two-period, Crossover, Withdrawal Study to Assess the Efficacy and Safety of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II (LAD II)Leukocyte Adhesion DeficiencyDrug: AVTX-803 (L-Fucose)Avalo Therapeutics, Inc.NULLRecruiting6 Months75 YearsAll4Phase 3United States